CSIMarket Company Name, Ticker, Competitors, else..
 
Seer Inc   (NASDAQ: SEER)
 
Price: $1.9500 $0.00 0.000%
Day's High: $1.9800000190734863 Week Perf: 0.52 %
Day's Low: $ 1.93 30 Day Perf: -10.14 %
Volume (M): 193,737 52 Wk High: $ 2.41
Volume (M$): $ 0 52 Wk Avg: $1.95
Open: $1.94 52 Wk Low: $1.55



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 90
 Revenues (TTM) (Millions $) 14
 Net Income (TTM) (Millions $) -68
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 1

Business Description


Seer Inc is a technology company that specializes in developing innovative solutions for virtual reality (VR) and augmented reality (AR) platforms. They focus on creating immersive and interactive experiences across various industries such as gaming, entertainment, education, and healthcare. Seer Inc aims to push the boundaries of how people interact with digital content and provide seamless and realistic simulations through their cutting-edge technology and expertise in the field of VR and AR.


   Company Address: 3800 Bridge Parkway Redwood City 94065 CA
   Company Phone Number: 453-0000   Stock Exchange / Ticker: NASDAQ SEER


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
A   -4.37%    
BIO   -1.06%    
ILMN   -1.2%    
PACB   -2.94%    
RVTY   -1.24%    
TXG        5.04% 
• View Complete Report
   



Clinical Study

Unraveling the Proteome Seer’s Proteograph Platform Propels Biomedical Discovery to New Heights

Published Fri, Nov 7 2025 1:09 PM UTC

In the realm of modern medicine, where the intricate web of biological processes governs health and disease, the need for holistic approaches to understanding human biology is paramount. At the recent Human Proteome Organization (HUPO) 2025 conference, Seer and its esteemed collaborators unveiled groundbreaking new data demonstrating the translational potential of deep prote...
Contract

From Deep Losses to Deeper Insights Seers Strategic Collaboration with Thermo Fisher

Published Wed, Nov 6 2024 9:03 PM UTC

Balanced Analysis of Seer s New Partnership Amid Financial Challenges In a strategic move aimed at revolutionizing the field of proteomics, Seer Inc. has entered into a co-marketing and sales agreement with Thermo Fisher Scientific. This collaboration promises unprecedented access to deep, unbiased proteomics at scale, which could potentially unlock new dimensions in human b...
Product Service News

Spaceflight Reveals New Insights into Precision Medicine and Biomarker Discovery: Impact on SpaceX

Published Tue, Jun 11 2024 3:12 PM UTC

SpaceX has ventured into uncharted territory with its Inspiration4 mission, sending civilians into space. Amidst the excitement surrounding this milestone achievement, a recent scientific breakthrough has emerged that provides differentiated insights into proteomic alterations during spaceflight. The analysis of seer proteograph and secretome profiles from the Inspiration4 m...
Product Service News

In a monumental stride within the landscape of biomedical research, Seer Technology Access Center has unvei...

Published Sun, Jun 2 2024 2:55 PM UTC

Understanding the Future of Cancer Detection: Seer s Groundbreaking Technological Integration In a monumental stride within the landscape of biomedical research, Seer Technology Access Center has unveiled data from PrognomiQs early cancer detection study, strongly highlighting the efficacy of their Proteograph XT Assay. This advancement, coupled with the implementation of th...
Clinical Study

Seer Proteograph: Unleashing the Power of Genetic Marker Mapping for Advancements in Drug and Biomarker Discovery

Published Tue, Feb 6 2024 1:00 PM UTC

In the pursuit of breakthrough drug development and the identification of effective biomarkers, the field of proteogenomics has gained significant momentum. In recent years, Weill Cornell Medicine spearheaded a remarkable study that utilized the innovative Seer Proteograph technology to enable unprecedented genetic marker mapping for proteogenomics research. This scientific ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 48.2
Working Capital Ratio 49.18
Leverage Ratio (MRQ) 0.14
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.6 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 159,744
Net Income per Employee (TTM) -755,156
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) 0.96
Asset Turnover Ratio (TTM) 0.04

Profitability Ratios Current
Gross Margin (MRQ) 48.55 %
Operating Margin (MRQ) -542.91 %
Net Margin (MRQ) -544.78 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Seer Inc's Segments
Product    1.81 % of total Revenue
Service    39.3 % of total Revenue
Other    6.03 % of total Revenue

  Seer Inc Outlook

On February 29 2024 the Seer Inc provided following guidance

Seer Inc. has recently released its fourth quarter and full-year financial results for 2023 and has also pro...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.